Clinical Trials at Carle Cancer Center

As of July 2026, 117 paid clinical trials are recruiting at Carle Cancer Center in Urbana, Illinois. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

117 clinical trials at Carle Cancer Center

·Clear filters·↓ Download CSV

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for Muscle Invasive Bladder Urothelial Carcinoma

491 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05987241·Phase 2, Phase 3·Recruiting

Apply to this trial

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for Advanced Malignant Solid Neoplasm

477 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: All ages

Code: NCT05564377·Phase 2·Recruiting

Apply to this trial

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

454 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05642572·Phase 2·Recruiting

Apply to this trial

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

for Resectable Lung Non-Small Cell Carcinoma

382 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06632327·Phase 3·Recruiting

Apply to this trial

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

for Clear Cell Renal Cell Carcinoma

415 locations incl. Phoenix

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06661720·Phase 3·Recruiting

Apply to this trial

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for Anatomic Stage II Breast Cancer AJCC v8

Drug: Durvalumab

541 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06058377·Phase 3·Recruiting

Apply to this trial

E-Mindfulness Approaches for Living After Breast Cancer

for Breast Cancer

362 locations incl. Phoenix

Sponsor: NRG Oncology

Sex: All·Age: 18 - 50

Code: NCT06748222·Phase 3·Recruiting

Apply to this trial

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

for Malignant Solid Neoplasm

384 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: All ages·Accepts healthy volunteers

Code: NCT06295367·Recruiting

Apply to this trial

Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer

for Miscellaneous Neoplasm, Nos

280 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT07091617·Recruiting

Apply to this trial

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

for Locally Advanced Lung Non-Small Cell Carcinoma

476 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05624996·Phase 3·Recruiting

Apply to this trial

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

for Pancreatic Acinar Cell Carcinoma

Drug: Olaparib

451 locations incl. Dayton

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04858334·Phase 2·Recruiting

Apply to this trial

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for Locally Advanced Cervical Adenocarcinoma

296 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT07061977·Phase 3·Recruiting

Apply to this trial

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

for Biochemically Recurrent Prostate Carcinoma

Drug: Apalutamide

342 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: Male·Age: 18+

Code: NCT04423211·Phase 3·Recruiting

Apply to this trial

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

for Pancreatic Neoplasm

408 locations incl. Birmingham

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 50 - 75

Code: NCT04239573·Recruiting

Apply to this trial

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for Ovarian Carcinoma

539 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 35 - 50

Code: NCT04251052·Recruiting

Apply to this trial

Family Communications After Genetic Testing

for Colon Adenocarcinoma

276 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT07143487·Recruiting

Apply to this trial

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

for Advanced Lung Non-Small Cell Carcinoma

319 locations incl. Fayetteville

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 70+

Code: NCT06096844·Phase 3·Recruiting

Apply to this trial

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

for Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma

321 locations incl. Gilbert

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06958328·Phase 3·Recruiting

Apply to this trial

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

Drug: Cemiplimab

386 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT06616584·Phase 2, Phase 3·Recruiting

Apply to this trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

336 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting

Apply to this trial

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

for Cardiotoxicity

577 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT03418961·Phase 3·Recruiting

Apply to this trial

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

for Mantle Cell Lymphoma

237 locations incl. Little Rock

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 60+

Code: NCT05976763·Phase 3·Recruiting

Apply to this trial

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

for Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Drug: Nivolumab

392 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 5 - 60

Code: NCT05675410·Phase 3·Recruiting

Apply to this trial

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

for Metastatic Renal Cell Carcinoma

323 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05327686·Phase 2·Recruiting

Apply to this trial

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

for Advanced Lung Non-Small Cell Carcinoma

Drug: Osimertinib

345 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03191149·Phase 2·Recruiting

Apply to this trial

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

for Acral Lentiginous Melanoma

Drug: Ipilimumab

331 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04511013·Phase 2·Recruiting

Apply to this trial

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

for Advanced Esophageal Adenocarcinoma

Drug: Nivolumab

373 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06203600·Phase 2, Phase 3·Recruiting

Apply to this trial

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

for Metastatic Clear Cell Renal Cell Carcinoma

387 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04510597·Phase 3·Recruiting

Apply to this trial

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

for Classic Follicular Lymphoma

Drug: Mosunetuzumab

270 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06337318·Phase 3·Recruiting

Apply to this trial

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

for Clinical Stage III Cutaneous Melanoma AJCC v8

Drug: Cabozantinib

223 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05136196·Phase 2·Recruiting

Apply to this trial

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

for Head and Neck Squamous Cell Carcinoma

200 locations incl. Gilbert

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06992427·Phase 3·Recruiting

Apply to this trial

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

for Chronic Lymphocytic Leukemia

Drug: Sonrotoclax

152 locations incl. Los Angeles

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 65+

Code: NCT07321652·Phase 3·Recruiting

Apply to this trial

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program

for Cigarette Smoking-Related Carcinoma

222 locations incl. Kingman

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05008848·Phase 3·Recruiting

Apply to this trial

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

for Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma

Drug: Atezolizumab

338 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT01810913·Phase 2, Phase 3·Recruiting

Apply to this trial

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

for Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

153 locations incl. Gilbert

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06532279·Phase 2·Recruiting

Apply to this trial

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

for Myelodysplastic Syndrome

141 locations incl. Berkeley

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06577441·Phase 2·Recruiting

Apply to this trial

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Drug: Venetoclax

225 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06317649·Phase 2·Recruiting

Apply to this trial

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

for Renal Pelvis and Ureter Urothelial Carcinoma

Drug: Durvalumab

258 locations incl. Kingman

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04628767·Phase 2, Phase 3·Recruiting

Apply to this trial

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

for Recurrent Lung Non-Small Cell Carcinoma

266 locations incl. Daphne

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18 Minutes+

Code: NCT06031688·Phase 2·Recruiting

Apply to this trial

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

for Castration-Sensitive Prostate Carcinoma

Drug: Apalutamide

195 locations incl. Tucson

Sponsor: Alliance for Clinical Trials in Oncology

Sex: Male·Age: 18+

Code: NCT06931340·Phase 3·Recruiting

Apply to this trial